DOSSIERS
Please find below our library of educational resources on PTTc
What is cTTP?
Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare thrombomicroangiopathy caused by an inherited deficiency of the VWF (von Willebrand Factor)-cleaving metalloprotease.
INFOGRAPHIC
What causes cTTP?
Congenital thrombotic thrombocytopenic purpura (cTTP) is caused by autosomal recessive mutations in the ADAMTS13 gene.
INFOGRAPHIC
What are the clinical consequences of cTTP?
The clinical presentation ranges from life-threatening, acute, overt TTP events to milder TTP manifestations, including thrombocytopenia, haemolytic anaemia, abdominal pain, headaches, and neurological symptoms.
INFOGRAPHIC
Unmet needs of patients with cTTP
Prophylaxis is a recommended approach for some patients with congenital thrombotic thrombocytopenic purpura (cTTP)
VIDEO
The long-term burden of disease
Patients with congenital thrombotic thrombocytopenic purpura (cTTP) experience disease- and treatment-related complications and burdens that have a negative impact on their health-related quality of life (HRQoL).
INFOGRAPHIC
Identifying patients with cTTP
The clinical presentation of congenital thrombotic thrombocytopenic purpura (cTTP) ranges from life-threatening, acute, overt thrombotic thrombocytopenic purpura (TTP) events to milder TTP manifestations, including thrombocytopenia, haemolytic anaemia, abdominal pain, headaches, and neurological symptoms.
INFOGRAPHIC
PRODUITS
Please find below information about our products indicated for the management of PTTc.
ADZYNMA Efficacy
ADZYNMA▼ is an enzyme replacement therapy (ERT) indicated for the treatment of A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA can be used for all age groups.1,*
INFOGRAPHIC
ADZYNMA Safety
ADZYNMA▼ is an enzyme replacement therapy (ERT) indicated for the treatment of A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA can be used for all age groups.1,*
INFOGRAPHIC
Prescribing ADZYNMA
ADZYNMA▼ is an enzyme replacement therapy (ERT) indicated for the treatment of A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA can be used for all age groups.1,*
INFOGRAPHIC
ADZYNMA Programme overview
ADZYNMA▼ is an enzyme replacement therapy (ERT) indicated for the treatment of “A disintegrin and metalloproteinase with thrombospondin motifs 13” (ADAMTS13) deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA can be used for all age groups.